S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
BREAKING: Tiny biotech successfully treats blindness (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
BREAKING: Tiny biotech successfully treats blindness (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
BREAKING: Tiny biotech successfully treats blindness (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
BREAKING: Tiny biotech successfully treats blindness (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
BREAKING: Tiny biotech successfully treats blindness (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
BREAKING: Tiny biotech successfully treats blindness (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
BREAKING: Tiny biotech successfully treats blindness (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
BREAKING: Tiny biotech successfully treats blindness (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
BREAKING: Tiny biotech successfully treats blindness (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
BREAKING: Tiny biotech successfully treats blindness (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
BREAKING: Tiny biotech successfully treats blindness (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
BREAKING: Tiny biotech successfully treats blindness (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
California governor rejects bill to give unemployment checks to striking workers
NASDAQ:TMCI

Treace Medical Concepts (TMCI) Stock Forecast, Price & News

$13.11
+0.91 (+7.46%)
(As of 09/29/2023 ET)
Compare
Today's Range
$12.61
$13.30
50-Day Range
$12.16
$23.26
52-Week Range
$11.85
$27.97
Volume
762,381 shs
Average Volume
624,710 shs
Market Capitalization
$806.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.30

Treace Medical Concepts MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
108.2% Upside
$27.30 Price Target
Short Interest
Healthy
3.83% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.74mentions of Treace Medical Concepts in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.72) to ($0.61) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

355th out of 972 stocks

Medical Devices Industry

1st out of 4 stocks


TMCI stock logo

About Treace Medical Concepts (NASDAQ:TMCI) Stock

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision; and Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

TMCI Price History

TMCI Stock News Headlines

Treace Medical Concepts (NASDAQ:TMCI) Shares Gap Up to $12.20
[BREAKING] Pentagon to Spend Billions on "Living Missile"
Air Force Magazine calls it "transformational." The Wall Street Journal calls it one of the Pentagon's "highest priorities." National Defense Magazine reports "Eye-popping budget" for it. This small company won the first contract to build them!
The Latest Analyst Ratings for Treace Medical Concepts
Treace Medical Concepts (NASDAQ: TMCI)
[BREAKING] Pentagon to Spend Billions on "Living Missile"
Air Force Magazine calls it "transformational." The Wall Street Journal calls it one of the Pentagon's "highest priorities." National Defense Magazine reports "Eye-popping budget" for it. This small company won the first contract to build them!
Treace Medical Concepts (TMCI) Receives a Buy from Truist Financial
TMCI - Treace Medical Concepts, Inc.
BTIG Sticks to Its Buy Rating for Treace Medical Concepts (TMCI)
What 5 Analyst Ratings Have To Say About Treace Medical Concepts
See More Headlines
Receive TMCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Treace Medical Concepts and its competitors with MarketBeat's FREE daily newsletter.

TMCI Company Calendar

Last Earnings
8/08/2023
Today
10/01/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical Devices
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TMCI
Fax
N/A
Employees
423
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$27.30
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+108.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-42,810,000.00
Pretax Margin
-25.32%

Debt

Sales & Book Value

Annual Sales
$141.84 million
Book Value
$1.09 per share

Miscellaneous

Free Float
43,888,000
Market Cap
$806.79 million
Optionable
Not Optionable
Beta
0.01
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. John T. TreaceMr. John T. Treace (Age 51)
    CEO, Founder & Director
    Comp: $1.04M
  • Mr. Mark L. Hair CPA (Age 53)
    Chief Financial Officer
    Comp: $628.6k
  • Mr. Aaron J. Berutti (Age 44)
    Sr. VP of Sales
    Comp: $519.41k
  • Mr. Terry W. Lubben (Age 58)
    Sr. VP of Operations
  • Ms. Julie D. Dewey (Age 62)
    Chief Communications & Investor Relations Officer
  • Mr. Scot M. Elder (Age 48)
    Chief Legal & Compliance Officer and Corp. Sec.
  • Mr. Nathan Minnich
    Sr. VP of Marketing
  • Mr. Daniel E. Owens (Age 51)
    Chief HR Officer
  • Mr. Jaime A. Frias (Age 61)
    Chief Bus. Devel. Officer
  • Dr. Sean F. Scanlan Ph.D. (Age 40)
    Chief Innovation Officer













TMCI Stock - Frequently Asked Questions

Should I buy or sell Treace Medical Concepts stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Treace Medical Concepts in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TMCI shares.
View TMCI analyst ratings
or view top-rated stocks.

What is Treace Medical Concepts' stock price forecast for 2023?

5 brokerages have issued 1-year target prices for Treace Medical Concepts' stock. Their TMCI share price forecasts range from $24.00 to $30.00. On average, they anticipate the company's share price to reach $27.30 in the next year. This suggests a possible upside of 108.2% from the stock's current price.
View analysts price targets for TMCI
or view top-rated stocks among Wall Street analysts.

How have TMCI shares performed in 2023?

Treace Medical Concepts' stock was trading at $22.99 at the beginning of 2023. Since then, TMCI stock has decreased by 43.0% and is now trading at $13.11.
View the best growth stocks for 2023 here
.

Are investors shorting Treace Medical Concepts?

Treace Medical Concepts saw a increase in short interest in September. As of September 15th, there was short interest totaling 1,660,000 shares, an increase of 28.7% from the August 31st total of 1,290,000 shares. Based on an average trading volume of 468,100 shares, the days-to-cover ratio is currently 3.5 days. Currently, 3.8% of the shares of the stock are short sold.
View Treace Medical Concepts' Short Interest
.

When is Treace Medical Concepts' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our TMCI earnings forecast
.

How were Treace Medical Concepts' earnings last quarter?

Treace Medical Concepts, Inc. (NASDAQ:TMCI) issued its earnings results on Tuesday, August, 8th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.03. The business earned $41.95 million during the quarter, compared to the consensus estimate of $40.84 million. Treace Medical Concepts had a negative trailing twelve-month return on equity of 39.29% and a negative net margin of 25.32%. The business's quarterly revenue was up 40.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.23) EPS.

What guidance has Treace Medical Concepts issued on next quarter's earnings?

Treace Medical Concepts updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $191.00 million-$197.00 million, compared to the consensus revenue estimate of $194.06 million.

When did Treace Medical Concepts IPO?

(TMCI) raised $150 million in an IPO on Friday, April 23rd 2021. The company issued 9,400,000 shares at $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and SVB Leerink and Stifel were co-managers.

What is Treace Medical Concepts' stock symbol?

Treace Medical Concepts trades on the NASDAQ under the ticker symbol "TMCI."

How do I buy shares of Treace Medical Concepts?

Shares of TMCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Treace Medical Concepts' stock price today?

One share of TMCI stock can currently be purchased for approximately $13.11.

How much money does Treace Medical Concepts make?

Treace Medical Concepts (NASDAQ:TMCI) has a market capitalization of $806.79 million and generates $141.84 million in revenue each year. The company earns $-42,810,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis.

How many employees does Treace Medical Concepts have?

The company employs 423 workers across the globe.

How can I contact Treace Medical Concepts?

Treace Medical Concepts' mailing address is 203 FORT WADE RD. SUITE 150, PONTE VEDRA FL, 32081. The official website for the company is www.treace.com. The company can be reached via phone at 904-373-5940 or via email at ir@treace.net.

This page (NASDAQ:TMCI) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -